Pharmacokinetics of 2‘,3’-Dideoxycytidine in Patients with AIDS and Related Disorders
- 1 September 1988
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 28 (9), 837-842
- https://doi.org/10.1002/j.1552-4604.1988.tb03225.x
Abstract
The clinical pharmacokinetics of 2′,3′-dideoxycytidine (DDC) were determined after oral and intravenous administration in ten patients with AIDS or AIDS-related complex. A high performance liquid chromatography (HPLC) analysis procedure using cation exchange extraction columns was used to measure DDC levels as low as 0.1 μM (21 ng/mL) in plasma and urine. The kinetics of DDC were linear over the dose range of 0.03 to 0.5 mg/kg. Total body clearance was 227 mL/min/m2 and did not change after 6 to 14 days of dosing. The volume of distribution at steady state was 0.54 L/kg. Plasma half-life was 1.2 hours, and bioavailability was 88%. Most (75%) of the parent drug was found unchanged in the urine. As a result, renal function could play a role in dose adjustment of DDC. Comparison is made between the kinetics of DDC and 3′-azido-2′,3′-dideoxythymidine (AZT). Similarities are noted in half-life and bioavailability. However, differences are observed for total body clearance, cerebrospinal fluid penetration, volume of distribution, metabolism, and recovery in urine.This publication has 9 references indexed in Scilit:
- PYRIMIDINE DIDEOXYRIBONUCLEOSIDES - SELECTIVITY OF PENETRATION INTO CEREBROSPINAL-FLUID1988
- PHASE I STUDIES OF 2',3'-DIDEOXYCYTIDINE IN SEVERE HUMAN IMMUNODEFICIENCY VIRUS INFECTION AS A SINGLE AGENT AND ALTERNATING WITH ZIDOVUDINE (AZT)The Lancet, 1988
- THE DISPOSITION AND METABOLISM OF 2',3'-DIDEOXYCYTIDINE, AN INVITRO INHIBITOR OF HUMAN T-LYMPHOTROPHIC VIRUS TYPE-III INFECTIVITY, IN MICE AND MONKEYS1987
- The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987
- Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: A Novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseasesCancer Cell, 1987
- ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEXThe Lancet, 1986
- Suramin Protection of T Cells in Vitro Against Infectivity and Cytopathic Effect of HTLV-IIIScience, 1984
- PharmacokineticsPublished by Informa UK Limited ,1982